San Diego-dependent Viking Therapeutics marked by itself as a significant competitor from the weight loss drug marketplace in February just after revealing promising data from the mid-phase demo of experimental drug VK2735, which recommended it rivaled—and outperformed—Novo and Lilly drugs when supplied for a weekly injection and in March the c